Herantis Pharma Oyj — Investor Relations & Filings

Herantis Pharma is a clinical-stage biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative conditions, with a primary focus on Parkinson's disease. The company's research is centered on its proprietary technology platform based on the cerebral dopamine neurotrophic factor (CDNF), which aims to stop or reverse disease progression. Its lead product candidate, HER-096, is a synthetic peptide engineered to cross the blood-brain barrier and address the underlying proteopathic mechanisms of the disease. The company's mission is to address significant unmet medical needs by creating innovative treatments for debilitating neurological disorders.